

Applicant: Robert E. Reiter et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 2

Please amend the subject application as follows:

**In the Claims:**

In compliance with 37 C.F.R. §1.121 for making amendments, Applicant's present all pending claims with status indicators.

Please amend claims 70-85 and add new claim 86 as follows:

--1 to 52. (Canceled) --

--53. (Previously presented) A protein fragment consisting of the amino acid residues selected from the group consisting of:

- a. amino acid residues 2 through 50 as described in SEQ ID NO:2;
- b. amino acid residues 85 through 123 as described in SEQ ID NO:2;
- c. amino acid residues 46 through 109 as described in SEQ ID NO:2;
- d. amino acid residues 18 through 98 as described in SEQ ID NO:2;
- e. amino acid residues 22 through 99 as described in SEQ ID NO:2;
- f. amino acid residues 21 through 50 as described in SEQ ID NO:2;
- g. amino acid residues 46 through 85 as described in SEQ ID NO:2;
- h. amino acid residues 50 through 64 as described in SEQ ID NO:2;
- i. amino acid residues 67 through 81 as described in SEQ ID NO:2;
- j. amino acid residues 21 through 99 as described in SEQ ID NO:2;
- k. amino acid residues 71 through 82 as described in SEQ ID NO:2;
- l. amino acid residues 85 through 99 as described in SEQ ID NO:2;
- m. amino acid residues 18 through 50 as described in SEQ ID NO:2;
- n. amino acid residues 46 through 98 as described in SEQ ID NO:2; or
- o. amino acid residues 85 through 98 as described in SEQ ID NO:2. --

--54. (Canceled) --

--55. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 2 through 50 as described in SEQ ID NO:2.--

Applicant: Robert E. Reiter et al.

U.S. Serial No.: 09/855,153

Filed: May 14, 2001

Page 3

- 56. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 85 through 123 as described in SEQ ID NO:2.--
- 57. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 46 through 109 as described in SEQ ID NO:2.--
- 58. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 18 through 98 as described in SEQ ID NO:2.--
- 59. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 22 through 99 as described in SEQ ID NO:2.--
- 60. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 21 through 50 as described in SEQ ID NO:2.--
- 61. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 46 through 85 as described in SEQ ID NO:2.--
- 62. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 50 through 64 as described in SEQ ID NO:2.--
- 63. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 67 through 81 as described in SEQ ID NO:2.--
- 64. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 21 through 99 as described in SEQ ID NO:2.--
- 65. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 71 through 82 as described in SEQ ID NO:2.--

Applicant: Robert E. Reiter et al.  
U.S. Serial No.: 09/855,153  
Filed: May 14, 2001  
Page 4

- 66. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 85 through 99 as described in SEQ ID NO:2.--
- 67. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 18 through 50 as described in SEQ ID NO:2.--
- 68. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 46 through 98 as described in SEQ ID NO:2.--
- 69. (Previously presented) The protein fragment of claim 53, consisting of amino acid residues 85 through 98 as described in SEQ ID NO:2.--
- 70. (Currently amended) A fusion protein consisting of a Prostate Stem Cell Antigen (PSCA) protein fragment fused to a heterologous amino-acids protein, wherein the PSCA protein fragment consists of the amino acid residues selected from the group consisting of:
- a. amino acid residues 2 through 50 as described in SEQ ID NO:2;
  - b. amino acid residues 85 through 123 as described in SEQ ID NO:2;
  - c. amino acid residues 46 through 109 as described in SEQ ID NO:2;
  - d. amino acid residues 18 through 98 as described in SEQ ID NO:2;
  - e. amino acid residues 22 through 99 as described in SEQ ID NO:2;
  - f. amino acid residues 21 through 50 as described in SEQ ID NO:2;
  - g. amino acid residues 46 through 85 as described in SEQ ID NO:2;
  - h. amino acid residues 50 through 64 as described in SEQ ID NO:2;
  - i. amino acid residues 67 through 81 as described in SEQ ID NO:2;
  - j. amino acid residues 21 through 99 as described in SEQ ID NO:2;
  - k. amino acid residues 71 through 82 as described in SEQ ID NO:2;
  - l. amino acid residues 85 through 99 as described in SEQ ID NO:2;
  - m. amino acid residues 18 through 50 as described in SEQ ID NO:2;

Applicant: Robert E. Reiter et al.

U.S. Serial No.: 09/855,153

Filed: May 14, 2001

Page 5

- n. amino acid residues 46 through 98 as described in SEQ ID NO:2; or
- o. amino acid residues 85 through 98 as described in SEQ ID NO:2. --

- 71. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 2 through 50 as described in SEQ ID NO:2. --
- 72. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 85 through 123 as described in SEQ ID NO:2. --
- 73. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 46 through 109 as described in SEQ ID NO:2. --
- 74. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 18 through 98 as described in SEQ ID NO:2. --
- 75. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 22 through 99 as described in SEQ ID NO:2. --
- 76. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 21 through 50 as described in SEQ ID NO:2. --
- 77. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 46 through 85 as described in SEQ ID NO:2. --
- 78. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 50 through 64 as described in SEQ ID NO:2. --
- 79. (Currently amended) Th fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 67 through 81 as described in SEQ ID NO:2. --

Applicant: Robert E. Reiter et al.

U.S. Serial No.: 09/855,153

Filed: May 14, 2001

Page 6

- 80. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 21 through 99 as described in SEQ ID NO:2. --
- 81. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 71 through 82 as described in SEQ ID NO:2. --
- 82. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 85 through 99 as described in SEQ ID NO:2. --
- 83. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 18 through 50 as described in SEQ ID NO:2. --
- 84. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 46 through 98 as described in SEQ ID NO:2. --
- 85. (Currently amended) The fusion protein ~~fragment~~ of claim 70 or 86, consisting of amino acid residues 85 through 98 as described in SEQ ID NO:2. --
- 86. (New) A fusion protein consisting of a Prostate Stem Cell Antigen (PSCA) protein fragment fused to an epitope tag, wherein the epitope tag is chosen from the group consisting of a heterologous protein, a C-myc tag and a 6Xhis tag. --